|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
It was observed that hTERT rs2736098 was associated with breast cancer risk (odds ratio [OR] = 1.88; p = 0.034), while rs2736100 and rs2853669 did not significantly differ between the groups.
|
27336831 |
2016 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
We also found rs2853669 and rs2736098 polymorphisms were significantly associated with breast cancer risk (OR = 0.76; 95% CI: 0.63-0.90; P = 0.002 and OR = 0.79; 95% CI: 0.72-0.87; P < 0.00001), respectively.
|
27461695 |
2017 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Collectively, our functional studies of the <i>TERT</i>-<i>CLPTM1L</i> breast cancer susceptibility locus describe rs2853669 as a functional variant of this association signal among three other potentially causal variants and demonstrate the versatile mechanisms by which <i>TERT</i> promoter variants may affect breast cancer risk.
|
28978027 |
2017 |
|
Breast Carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
In this study, it was found that there was no statistical difference between hTERT rs2736109 G>A, rs2735940 T>C, rs2853669 A>G, rs2736098 G>A, and rs2736100 T>G polymorphisms that can be associated with risk of BC.
|
29506639 |
2018 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
A common single-nucleotide polymorphism in the telomerase reverse transcriptase (TERT) promoter, rs2853669 influences patient survival rates and the risk of developing cancer.
|
26575952 |
2016 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Collectively, our functional studies of the <i>TERT</i>-<i>CLPTM1L</i> breast cancer susceptibility locus describe rs2853669 as a functional variant of this association signal among three other potentially causal variants and demonstrate the versatile mechanisms by which <i>TERT</i> promoter variants may affect breast cancer risk.
|
28978027 |
2017 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
We also found rs2853669 and rs2736098 polymorphisms were significantly associated with breast cancer risk (OR = 0.76; 95% CI: 0.63-0.90; P = 0.002 and OR = 0.79; 95% CI: 0.72-0.87; P < 0.00001), respectively.
|
27461695 |
2017 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
However, we identified a modifying effect of rs2853669 on <i>TERTp</i> mutations in that, among cancer patients with <i>TERTp</i> mutations, only those carrying the TT genotype had a poor survival (Hazard ratio = 1.56, 95% confidence interval = 1.06-2.28); subgroup analyses by cancer type also supported these results.
|
28881610 |
2017 |
|
Glioblastoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
|
26914704 |
2016 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The results of this meta-analysis suggest that the TERT rs2853669 polymorphism is associated with a significantly increased risk of cancer, particularly lung cancer, in Asian populations.
|
29534075 |
2018 |
|
Glioblastoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
|
25681309 |
2015 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
Glioblastoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
|
26608520 |
2016 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
The results of this meta-analysis suggest that the TERT rs2853669 polymorphism is associated with a significantly increased risk of cancer, particularly lung cancer, in Asian populations.
|
29534075 |
2018 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Subsequent analyses also did not reveal any association between rs2853669 and overall cancer prognosis.
|
28881610 |
2017 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
We observed an association of allele rs2853669 C with increased risk of prostate cancer (co-dominant model TC vs. TT OR = 1.65, P = 0.002; additive model OR = 1.42, P = 0.005; dominant model: OR = 1.64, P = 0.001) and allele rs7726159 A with reduced risk of this malignancy (сo-dominant model: AA vs. CC OR = 0.42, P = 0.002; additive model: OR = 0.69, P = 0.002; dominant model: OR = 0.67, P = 0.01; recessive model: OR = 0.48, P = 0.005).
|
25296732 |
2015 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
In this study, it was found that there was no statistical difference between hTERT rs2736109 G>A, rs2735940 T>C, rs2853669 A>G, rs2736098 G>A, and rs2736100 T>G polymorphisms that can be associated with risk of BC.
|
29506639 |
2018 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
It was observed that hTERT rs2736098 was associated with breast cancer risk (odds ratio [OR] = 1.88; p = 0.034), while rs2736100 and rs2853669 did not significantly differ between the groups.
|
27336831 |
2016 |
|
Glioblastoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Pre-operative MRIs of 64/67 genetically confirmed primary GBM patients (51/67 TERT-mutated with rs2853669 polymorphism) were analyzed according to Visually AcceSAble Rembrandt Images (VASARI) ( https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project ) imaging criteria by three radiological raters.
|
28894890 |
2017 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
A common single-nucleotide polymorphism in the telomerase reverse transcriptase (TERT) promoter, rs2853669 influences patient survival rates and the risk of developing cancer.
|
26575952 |
2016 |
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
TERT rs2853669 polymorphism was found in 44.4% of tumors.
|
25448848 |
2015 |
|
Primary malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
The results of this meta-analysis suggest that the TERT rs2853669 polymorphism is associated with a significantly increased risk of cancer, particularly lung cancer, in Asian populations.
|
29534075 |
2018 |
|
Malignant neoplasm of lung
|
|
0.030 |
GeneticVariation
|
BEFREE |
The effect of rs2853669 on lung cancer</span> risk was significant in younger individuals (OR=1.73, 95% CI=1.18-2.54, P=0.005) and adenocarcinoma (OR=1.50, 95% CI=1.07-2.07, P=0.02).
|
26425038 |
2015 |
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Interleukin-6 (IL-6) expression regulated by TERT promoter status and polymorphism, what leads us to think that TERT and IL-6 plays a significant role in GBM, where specific SNPs increase the risk of developing GBM while the rs2853669 SNP and specific mutations in the TERT promoter of the tumor lead to shorter survival.
|
26143636 |
2015 |